Whitepapers

A recent study by Morning Consult finds that >54% of US adults would be willing to participate in a clinical trial if it had a 30-minute-or-less commute. This is quite striking, given that <4% of the 328 million people in America are actively participating in clinical research today. The solution? - An accessible, intuitive digital clinical platform that connects sponsors, sites & patients, and replaces burdensome paper forms and physical visits with electronic consents (eConsent), electronic Clinical Outcome Assessments (eCOA’s), and remote visits (TeleVisits). Find out how Medable, the recognized industry leaders in Decentralized Clinical trials, can partner with your organization to digitally transform your clinical protocols. Your research teams can experience benefits such as; improved patient experience, higher quality outcomes data, & savings of US$25,000,000+ for individual studies. Download the White Paper now to learn how.

Using a pre-packed column platform enables seamless scale-up for downstream process purification. We demonstrate that neither the capacity of the packed resin nor the separation efficiency is affected when increasing the column volume.

In this application note we show how flow imaging microscopy and FlowCam can help analyze particles in biotherapeutic samples. To demonstrate this ability, a simulated protein formulation consisting of silicone oil microdroplets spiked in a protein formulation was prepared and run on a FlowCam 8100 FIM instrument and analyzed with VisualSpreadsheet software.

In this white paper, we utilize FlowCam LO to obtain simultaneous Flow imaging Microscopy (FIM) and LO measurements of a single sample. The results demonstrate that LO can undersize or even completely fail to detect highly transparent particles such as ETFE and some protein aggregates that FIM easily detects. These results highlight the importance of pairing LO measurements with an orthogonal technique like FIM.

In this white paper, we demonstrate the analysis capabilities of FlowCam Nano for biotherapeutic formulation development. This study compares the results from FlowCam Nano with those from FlowCam 8100 when analyzing samples containing protein aggregates, sucrose particles, and bacteria. We also demonstrate the consistency of the particle concentration measurements with FlowCam Nano and how the instrument may also be used to determine relative particle concentrations in samples.

In our new white paper, we present detailed performance results for FlowCam's Artificial Intelligence software, VisualAI, using images of different protein aggregates including monoclonal and polyclonal antibodies and silicone oil that were obtained with multiple FlowCam 8100 instruments. We also demonstrate VisualAI’s effectiveness at measuring protein aggregate content in samples with known ratios of protein aggregates and silicone oil droplets.

The clinical value of biologics for the treatment of many disease indications has been accompanied by phenomenal sales. By 2026, the global market for biologics is projected to increase to $537 billion. However, getting a promising drug candidate can be daunting. This white paper details how to optimize formulation development and tech transfer to ensure successful biologics production.